In a finding that could alter treatment for heart patients, those who took the anticlotting drug rivaroxaban daily after a heart attack or life-threatening chest pain had a lower risk of dying or suffering another heart attack than patients who took a placebo, according to researchers. C. Michael Gibson, HMS associate professor of medicine at Beth Israel Deaconess Medical Center and Jessica Mega, HMS assistant professor of medicine at Brigham and Women’s Hospital, are study co-authors.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure